Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

17%

1 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

Phase 2
4(80.0%)
Phase 3
1(20.0%)
5Total
Phase 2(4)
Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials
NCT05994339Phase 2Unknown

Radiotherapy Combined With Almonertinib for Stage III EGFR-Mutated Lung Cancer

Role: lead

NCT05934461Completed

A Retrospective Study of Radiotherapy Combined With EGFR-TKI for Stage III EGFR Mutant Lung Cancer

Role: lead

NCT05527470Phase 3Recruiting

Induction Chemotherapy Followed by IMRT or Concurrent Chemoradiotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma

Role: collaborator

NCT05097209Phase 2Recruiting

Camrelizumab for the Treatment of Locally Advanced Nasopharyngeal Carcinoma

Role: collaborator

NCT04350190Phase 2Completed

Apatinib Combined With PD-1 in the Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma

Role: collaborator

NCT03612219Phase 2Unknown

Adjuvant Treatment of Apatinib in Nasopharyngeal Carcinoma

Role: collaborator

All 6 trials loaded